Renoprotective effects of pentoxifylline in the PREDIAN trial

Research output: Contribution to journalShort SurveyOtherpeer-review

Abstract

The PREDIAN trial investigated the renoprotective effects of pentoxifylline, in addition to renin-angiotensin system blockade, in patients with type 2 diabetes mellitus and chronic kidney disease. This promising approach resulted in a reduction in the rate of decline in estimated glomerular filtration rate and a significant decrease in albuminuria.

Original languageEnglish
Pages (from-to)547-548
Number of pages2
JournalNature Reviews Nephrology
Volume10
Issue number10
DOIs
Publication statusPublished - 1 Jan 2014
Externally publishedYes

Cite this

@article{84140166c27a4131874f3e61dc12c91f,
title = "Renoprotective effects of pentoxifylline in the PREDIAN trial",
abstract = "The PREDIAN trial investigated the renoprotective effects of pentoxifylline, in addition to renin-angiotensin system blockade, in patients with type 2 diabetes mellitus and chronic kidney disease. This promising approach resulted in a reduction in the rate of decline in estimated glomerular filtration rate and a significant decrease in albuminuria.",
author = "Cooper, {Mark E.} and Tony He",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/nrneph.2014.162",
language = "English",
volume = "10",
pages = "547--548",
journal = "Nature Reviews Nephrology",
issn = "1759-5061",
publisher = "Nature Publishing Group",
number = "10",

}

Renoprotective effects of pentoxifylline in the PREDIAN trial. / Cooper, Mark E.; He, Tony.

In: Nature Reviews Nephrology, Vol. 10, No. 10, 01.01.2014, p. 547-548.

Research output: Contribution to journalShort SurveyOtherpeer-review

TY - JOUR

T1 - Renoprotective effects of pentoxifylline in the PREDIAN trial

AU - Cooper, Mark E.

AU - He, Tony

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The PREDIAN trial investigated the renoprotective effects of pentoxifylline, in addition to renin-angiotensin system blockade, in patients with type 2 diabetes mellitus and chronic kidney disease. This promising approach resulted in a reduction in the rate of decline in estimated glomerular filtration rate and a significant decrease in albuminuria.

AB - The PREDIAN trial investigated the renoprotective effects of pentoxifylline, in addition to renin-angiotensin system blockade, in patients with type 2 diabetes mellitus and chronic kidney disease. This promising approach resulted in a reduction in the rate of decline in estimated glomerular filtration rate and a significant decrease in albuminuria.

UR - http://www.scopus.com/inward/record.url?scp=84926261689&partnerID=8YFLogxK

U2 - 10.1038/nrneph.2014.162

DO - 10.1038/nrneph.2014.162

M3 - Short Survey

VL - 10

SP - 547

EP - 548

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-5061

IS - 10

ER -